RxDoctor Payments Data

Jessica Curti

Family Medicine · Reno, NVNPI 1851524235

Payments from drug & device makers

$479in general payments, 2019–2025

Across 24 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$122
  • AbbVie$109
  • Pfizer$77
  • Exact Sciences$50
  • GSK$38
  • Abbott$38
  • plus $46 from 2 others

What the payments were for

  • Food & beverage$479100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC7$122
AbbVie(2 entities)5$109
Pfizer4$77
Exact Sciences3$50
GSK2$38
Abbott1$38
Boehringer Ingelheim1$23
Teva Pharmaceuticals USA, Inc.1$22

How this compares

$479 in reported general payments places this provider in the 55th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$138,557
Medicare patients
379
Services billed
2,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide85$138,565
OzempicSemaglutide58$81,120
XareltoRivaroxaban21$30,544
EliquisApixaban17$21,840
TrulicityDulaglutide15$21,207
JanuviaSitagliptin Phosphate11$17,639
FarxigaDapagliflozin Propanediol18$13,855
EntrestoSacubitril/Valsartan13$13,482
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$8,337
SymbicortBudesonide/Formoterol Fumarate21$7,224
TradjentaLinagliptin11$6,707
Atorvastatin Calcium358$5,326
Levothyroxine Sodium460$4,891
SynthroidLevothyroxine Sodium27$3,581
Esomeprazole Magnesium11$3,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$122$159,772100 claims
PfizerEliquis, Paxlovid$77$23,26939 claims
Boehringer IngelheimTradjenta$23$6,70711 claims
AbbVieSynthroid$109$3,58127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 902 family medicine providers in Nevada.

Other family medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →